海外の治験の状況「1」での検索結果
2039件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Immunologic, genetic and bowel microbes as predictors of the treatment response for TNFalpha-blocking drugs in patients with Crohn’s disease or ulcerative colitis
- Ulcerative colitis and Crohn's disease MedDRA version: 19.0 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10058815 Term: Crohn's disease acute episode System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10057035 Term: Crohn's ileocolitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10011405 Term: Crohn's enteritis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10011406 Term: Crohn's ileitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10076318 Term: Crohn's disease relapse System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10011402 Term: Crohn's disease (colon) System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10075466 Term: Fistulising Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10066678 Term: Acute ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10075465 Term: Fistulizing Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0 Level: LLT Classification code 10011400 Term: Crohn's colitis System Organ Class: 10017947 - Gastrointe;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Finland
- 2016-04-15
Authorised
- A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency
- Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency MedDRA version: 19.0 Level: LLT Classification code 10014563 Term: Emphysema pulmonary System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Argentina, Australia, Brazil, Canada, Denmark, Estonia, France, Germany, New Zealand, Poland, Romania, Russian Federation, Spain, Sweden, United States
- 2016-01-29
Authorised
- A study to evaluate the drug Mongersen (GED-0301) for the treatment of Crohn’s disease
- Active Crohn's disease MedDRA version: 20.0 Level: LLT Classification code 10021315 Term: Ileitis terminal System Organ Class: 100000016693 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2015-11-18
Authorised
- PD interaction of DMED and REMI
- We will include 30 healthy volunteers (American Society of Anesthesiologists 1) stratified to age groups to different sequence of anesthesia regimen;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Equipment and Supplies [E07]
- Netherlands
- 2017-04-04
Authorised
- Potentiation of procedural motor learning by pharmacological neuromodulation and brain stimulation - Potentiation of procedural motor learning
- Healthy volunteers Patients in the chronic stage (> 1 year) after stroke
- Germany
- 2005-08-08
Authorised
- A randomised, double-blind, placebo-controlled, five parallel groups study investigating the efficacy and safety of BI 1356 BS (1mg, 5mg and 10mg administered orally once daily) over 12 weeks as add-on therapy in patients with type 2 diabetes and insufficient glycaemic control despite metformin therapy, including an open-label glimepiride treatment arm.
- Patients with type 2 diabetes MedDRA version: 8.1 Level: PT Classification code 10012613 Term: Diabetes mellitus non-insulin-dependent
- Germany, Sweden, United Kingdom
- 2006-02-17
Authorised
- Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBD
- Inflammatory Bowel Disease Crohn Disease, Ulcerative Colitis MedDRA version: 6.1 Level: PT Classification code 10021972
- Italy
- 2006-01-31
Authorised
- Essai de Phase III, Multicentrique, Randomisé, comparant la Chimiothérapie d’induction par Docétaxel, Cisplatine et 5-Fluorouracile (TPF) suivie d’une chimio-radiothérapie concomitante versus une chimio-radiothérapie concomitante seule, dans les cancers du nasopharynx classés T2b, T3, T4 et/ou avec envahissement ganglionnaire (>> N1) - NPC 2006
- Patients atteints de cancers du nasopharynx classés T2b; T3;T4 ; OMS II-III et /ou avec envahissement ganglionnaire (Nsupérieur ou égal à 1) MedDRA version: 9.1 Level: LLT Classification code 10026161 Term: Malignant neoplasm of nasopharynx
- France
- 2007-09-06
Authorised
- Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPP-IV inhibitor RO4876904 in patients with type 2 diabetes
- Type 2 diabetes MedDRA version: 9.1 Level: LLT Classification code 10012613 Term: Diabetes mellitus non-insulin-dependent
- Spain, United Kingdom
- 2007-05-16
Authorised
- Efficacy of Fructose metabolizing enzymatic product Fructosin(R) with Fructose malabsorption ( Wirkamkeit des Fruktose-abbauenden Enzympräparates Fructosin® bei Fruktose-Malabsorption) - Fruktosin Study
- Fructose Intolerance; Incapability to digest fructose contained in food
- Austria
- 2008-11-18
Authorised
- The precision of three pain scales as a function of sedation
- This is a patient study in patients with a planned operation under general anaesthesie including healthy or merately ill patients (anaesthesia risk classification ASA 1-3). Pain self assessment as a function of sedation by IMP is studied.
- Austria
- 2008-08-26
Authorised
- Effects on Endocrine-Metabolic Parameters and Body Composition of the Addition of Low-Dose Pioglitazone to Flutamide-Metformin Therapy in Young Women with Hyperinsulinemic Ovarian Hyperandrogenism and Cardiovascular Risk - Pioglitazone in PCOS
- Polycystic Ovary Syndrome includes anovulatory hyperandrogenism, hyperinsulinemia and/or dyslipidemia. Adiponectin and interleukin-6 are adipocytokines that have been related to abdominal fat excess and/or impaired insulin sensitivity. These cytokines -together with other indices of low-grade inflammation-, sucj as C-reactive protein (CRP), and the neutrophil count, contribute to link insulin-resistant states with cardiovascular disease risks.
- Spain
- 2005-10-05
Authorised
- Continuous peritoneal infusion of ropivacaine following laparoscopy for postoperative analgesia in children: a randomized, double-blind, placebo-controlled study. - Peritoneal infusion of ropivacaine following laparoscopy in children.
- Children aged over 1 year, undergoing elective abdominal laparoscopic surgery. MedDRA version: 9.1 Level: LLT Classification code 10023693 Term: Laparoscopy
- Italy
- 2008-06-12
Authorised
- Magnesiumsulfaatti-infuusio lasten äkillisen bronkusobstruktion hoidossa
- Tutkimukseen rekrytoidaan OYS:n lasten päivystyspoliklinikalle tulevat lapset, joilla hengitystieinfektioon liittyvä bronkusobstruktio, iIkä 0.5- 4 vuotta ja tavanomaisen polikliinisen lääkityksen jälkeen oirepisteet (RDAI) 6 tai enemmän. Lisäksi oltava vähintään 1 kk tauko säännöllisen inhaloitavan steroidin tai montelukastin käytössä. Satunnaistetaan saamaan joko magnesiumsulfaattia 40mg/kg i.v. 20 min infuusiona tai lumeinfuusio (0.9% NaCl). MedDRA version: 12.1 Level: LLT Classification code 10047928 Term: Wheezy bronchitis
- Finland
- 2010-09-21
Authorised
- -
- Chronic Hepatitis C Genotype 1 patients MedDRA version: 15.0 Level: LLT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Australia, Belgium, France, Germany, Hungary, Italy, Poland, Romania, Spain, Taiwan, Turkey, United Kingdom, United States
- 2010-06-21
Authorised
- Automimmune Diabetes Accelerator Prevention Trial (adAPT)
- Children aged 5 to 16 on entry to the RCT with the presence of two or more islet-related autoantibodies which confers a 40% risk of developing type 1 diabetes in five years. MedDRA version: 18.0 Level: LLT Classification code 10036481 Term: Pre-diabetes System Organ Class: 100000004861 ;Therapeutic area: Body processes [G] - Biological Phenomena [G16]
- United Kingdom
- 2015-09-28
Authorised
- A study evaluating the of safety and efficacy of LNP023 in patients with a kidney disorder called IgAN nephropathy
- Primary IgA Nephropathy br>MedDRA version: 20.0 Level: HLGT Classification code 10029149 Term: Nephropathies System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belgium, China, Denmark, Finland, Germany, Korea, Republic of, Netherlands, Norway, Singapore, Sweden, Taiwan, Thailand, United Kingdom, United States
- 2017-11-23
Authorised
- A study evaluating the of safety and efficacy of LNP023 in patients with a kidney disorder called IgAN nephropathy
- Primary IgA Nephropathy br>MedDRA version: 20.0 Level: HLGT Classification code 10029149 Term: Nephropathies System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Argentina, Australia, Belgium, China, Denmark, Finland, Germany, Korea, Republic of, Netherlands, Norway, Singapore, Sweden, Taiwan, Thailand, United Kingdom, United States
- 2017-10-17
Authorised
- A Trial on Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors
- Phase 1 – Part A dose escalation in patients with metastatic or locally advanced solid tumor for which no standard therapy exists or standard therapy has failed. Phase 2 - Part B unresectable or metastatic cervical cancer with disease progression after a platinum-based first-line regimen. MedDRA version: 20.0 Level: LLT Classification code 10008236 Term: Cervical cancer stage IV System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10008231 Term: Cervical cancer recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Hungary, Poland, Spain, Ukraine, United States
- 2018-11-23
Authorised
- A trial of AGEN1884 with AGEN2034 in Advanced Tumors
- Phase 1 – Part A dose escalation in patients with metastatic or locally advanced solid tumor for which no standard therapy exists or standard therapy has failed. Phase 2 - Part B unresectable or metastatic cervical cancer with disease progression after a platinum-based first-line regimen. MedDRA version: 20.0 Level: LLT Classification code 10008236 Term: Cervical cancer stage IV System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10008231 Term: Cervical cancer recurrent System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Hungary, Poland, Spain, Ukraine, United States
- 2018-09-26
